TAK vs. GMAB, ALNY, TEVA, BGNE, BMRN, VTRS, UTHR, SRPT, RDY, and ZTS
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.
Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
Genmab A/S received 43 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 60.85% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of 6.18%. Takeda Pharmaceutical's return on equity of 18.90% beat Genmab A/S's return on equity.
Genmab A/S has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Genmab A/S currently has a consensus target price of $48.50, indicating a potential upside of 72.41%. Takeda Pharmaceutical has a consensus target price of $14.00, indicating a potential upside of 6.54%. Given Takeda Pharmaceutical's higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.
In the previous week, Genmab A/S had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Genmab A/S and 1 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.73 beat Genmab A/S's score of 0.44 indicating that Genmab A/S is being referred to more favorably in the media.
7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Genmab A/S beats Takeda Pharmaceutical on 13 of the 17 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Takeda Pharmaceutical Competitors List
Related Companies and Tools